Multinational company regional headquarters in Shanghai are increasing their efforts to deeply cultivate the Chinese market, transforming from exhibitors to investors in manufacturing, healthcare, and other regions
In May of this year, Siemens Medical announced that it would add a total investment of over 1 billion yuan to build a new high-end medical equipment research and manufacturing base in Nanshan District, Shenzhen. Through this investment, it will increase local investment in magnetic resonance research and production, and meet the diverse medical needs of local patients at a "Chinese speed"; Recently, the Danaher diagnostic platform China R&D and manufacturing base project located in Suzhou Industrial Park announced that it is about to be completed and will be put into use within this year. This base is currently the largest single investment project of Danaher Group in China, and is a super factory that integrates Industry 4.0 intelligent management and Danaher business system DBS management
The reporter learned from some multinational regional headquarters in Shanghai that have long been rooted in Shanghai and deeply rooted in China that participating in the CIIE has accelerated the speed of enterprises transforming from exhibitors to investors; In the face of increasing downward pressure on global foreign direct investment, they are voting with genuine gold and silver, and full of sincerity: China, as a hot land for foreign investment, still has a strong "magnetic force".
In 2022, Danaher's localization strategy deepened once again and fully launched the "Creating China" strategy, clearly proposing two "80" goals, that is, 80% of future product sales in China will be produced in China; 80% of the raw materials and components used by local factories are purchased domestically.
As the countdown to the opening of the 6th China International Import Expo approaches 100 days, Danaher, who has participated in five consecutive CIIE sessions, has released a phased achievement in the localization strategy of "Creating China". According to Wei Chunyan, Vice President of Danaher's Chinese Government Affairs, more than a year after the launch of the strategy of "creating and upgrading China", Danaher has continued to increase its footprint in the local market, invested in the establishment of new production bases, research and development centers and innovation centers, and has also actively expanded its medical and life science business layout and investment in Changsanjiao, Beijing Tianjin Hebei, Guangdong Hong Kong Macao Greater Bay Area, and the "the Belt and Road" Chengdu Chongqing Twin Cities Economic Circle.
Danaher Group booth at the 5th CIIE.
It is understood that this year coincides with Beckmann Kurt, a medical diagnostic company under Danaher Group, entering China for 40 years. Since its establishment in Suzhou in 1997, Beckman Kurt has now achieved local production of all major equipment, relying on Danaher's localization strategy of "creating and upgrading China". This year marks the 30th anniversary of the completion of Leica Biosystems Shanghai R&D and production base, a pathological diagnosis company under Danaher Group. At present, the expansion plan of Leica's Shanghai R&D production base is steadily advancing, with a total investment of over 100 million yuan to expand production lines and capacity, making more Chinese quality a world standard. In addition, in July this year, SCIEX, a company under Danaher and an innovator in the field of life science analysis technology, officially delivered its first localized mass spectrometry product in China.
At the 5th China International Import Expo in 2022, Danaher's biotechnology company Cytova Situofan announced a plan to increase its capital by 60 million yuan in China. After the increase, the Cytova China Science and Technology Innovation Center will have a total investment of nearly 100 million yuan and will be officially launched in the second half of 2023.
Aiken Organic Silicon Co., Ltd. will participate in the CIIE for the sixth time this year, and the booth area will continue to expand, from the initial 36 square meters to 252 square meters this year. In the second quarter of 2022, Aiken announced that it will further increase its investment in China, investing over 100 million yuan to build its flagship Asia Pacific R&D center located in Shanghai.
"This move aims to comprehensively upgrade the scientific research system and equipment of Aiken Organosilicon in China, introduce outstanding R&D talents from around the world, and provide more efficient, flexible, and close product research and application support for the Chinese and other markets in the Asia Pacific region. It meets the growing demand for advanced organosilicon products and technologies in new energy vehicles, medical health and personal care, textiles and leather, 3D printing, and other industries." Li Pei, R&D Director of Aiken Organosilicon Co., Ltd. in the Asia Pacific region, introduced that the Asia Pacific R&D center is currently under construction, located in the Xinzhuang Industrial Zone of Shanghai. The first phase of the project covers an area of approximately 6600 square meters and is expected to be completed by the end of 2023. It is expected that the number of R&D personnel will double compared to the current number in the next three years.
As a global protein expert, Tyson Foods has participated in three consecutive CIIE. At the 4th China International Import Expo, Tyson China announced the official start of its first year of digital transformation. In the same year, they announced the simultaneous construction of three smart factories located in Shandong, Jiangsu, and Hubei, helping to achieve Tyson's new full industry chain layout plan in Hubei and the digital upgrading and transformation of existing factories in Jiangsu, Shandong, and other places. In October 2022, Tyson China's first smart factory was completed and put into operation in Rizhao, Shandong, with a project investment of 30 million US dollars. In June 2023, Tyson Xiaogan Smart Factory and Nantong Smart Factory were officially put into operation, with a total investment of nearly 714 million yuan for the Xiaogan Smart Factory project and nearly 300 million yuan for the Nantong Smart Factory project.
"At the 6th China International Import Expo, we will further showcase the phased achievements of Tyson China's digital transformation, continuously deepen the specific implementation of the national production and business layout, including Tyson China's smart factory's assistance in food industrialization transformation, sustainable practices of energy conservation and carbon reduction, and actively expanding the business achievements of overseas meat export trade." Zhou Quan, Senior Director of Public Relations at Tyson Enterprise Management Co., Ltd., introduced.
Est é e Lauder has participated in the second, third, fourth, and fifth consecutive CIIE. In December 2022, Est é e Lauder's China Innovation and Research Center was officially unveiled in Shanghai. This is the third upgrade since the Est é e Lauder R&D center was established in Shanghai in 2005 and upgraded to an Asia Pacific R&D center in 2011.
Est é e Lauder Group was awarded the "Zero Carbon Venue" certificate at the 5th CIIE.
According to reports from relevant sources in Minhang District, as a major industrial project under construction in Shanghai, the Est é e Lauder Logistics Center project in Xinzhuang Industrial Zone has partially topped out its structure since its construction began in the second half of last year. The Est é e Lauder Logistics Center project is invested and constructed by Xinzhuang Industrial Zone Economic and Technological Development Co., Ltd. Est é e Lauder stated that the implementation of this project has tailored a first-class modern logistics center for Est é e Lauder Company, which can solve the supply chain operation, sorting, logistics and other problems caused by the rapid growth of sales volume.
"Every year at the China International Import Expo, we introduce the latest and most cutting-edge technologies from around the world to our Chinese customers through this platform. However, the exhibition is just the beginning. Over the years, we have been working and will continue to adhere to the integration of Siemens Healthcare's global top innovation with Chinese wisdom, ultimately achieving 'global co creation'." Siemens Healthcare's President for Greater China, Wang Hao, said, "We are full of confidence in the development potential of the Chinese market and will continue to leverage the advantages of global network and innovation capabilities to support China's connectivity with the world."
